Literature DB >> 1336891

Azithromycin pharmacokinetics and penetration to lymph.

T Bergan1, N P Jørgensen, W Olszewski, Y Zhang.   

Abstract

The study of pharmacokinetics of azithromycin and penetration to peripheral human lymph was carried out in 14 healthy male volunteers taking 1 g orally after overnight fasting. Samples were analyzed by microbiological assay. The mean peak concentrations were 0.82 +/- 0.23 mg/l after 1.7 +/- 0.5 h in serum and 0.22 +/- 0.07 mg/l after 3.1 h in lymph. Nine of the 14 subjects showed a second and lower serum peak indicating the existence of enterohepatic circulation. The total areas under the serum concentrations curves (AUCs) till infinity were 7.9 +/- 3.1 mg. h/l compared to 4.4 +/- 1.2 mg.h/l in lymph. The mean lymph AUC was 68.1 +/- 20.7% of the serum AUC indicating a penetration ratio of 0.68. However, the actual amounts penetrating the tissues were much higher than this ratio suggests. Thus, after 6 h 81% of the drug was within the tissue compartment and after 120 h, 63% of the azithromycin was still present in the tissue compartment. The urinary recovery of azithromycin was 14.7 +/- 7.7% during the first 48 h. The serum curves and lymph curves displayed a distinctly slower phase of elimination after 12 h. The mean serum half-life was 5.4 +/- 3.4 h during the first 12 h (after the peak), whereas the value was 44.2 +/- 10.1 h during the interval 12-120 h. The corresponding half-life values for the peripheral lymph were 5.4 +/- 2.2 h and 50.8 +/- 11.6 h. Azithromycin possesses key pharmacokinetic properties that are prerequisites for a convenient once-daily dosage schedule which may improve patient compliance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336891

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  2 in total

1.  Safety, toleration, and pharmacokinetics of intravenous azithromycin.

Authors:  D R Luke; G Foulds; S F Cohen; B Levy
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

2.  Comparison of gastrointestinal side effects from different doses of azithromycin for the treatment of gonorrhoea.

Authors:  Jason J Ong; Ivette Aguirre; Magnus Unemo; Fabian Y S Kong; Christopher K Fairley; Jane S Hocking; Eric P F Chow; Warittha Tieosapjaroen; Jenny Ly; Marcus Y Chen
Journal:  J Antimicrob Chemother       Date:  2022-06-29       Impact factor: 5.758

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.